The JADE101 Phase 1 data is a material pipeline catalyst — ~70% IgA reduction with Q12W dosing potential positions it as best-in-class in IgAN. The accelerated JADE301 timeline adds a second near-term catalyst. Monitor for FDA feedback on Phase 3 design and interim JADE101 Phase 2 data in 2027. The $172.5M raise removes near-term financing risk but adds ~19% dilution vs Q1.
Price Chart
Executive Summary
Jade Biosciences reported Q2 2026 results with net loss of -$0.76 per share (vs -$0.86 YoY), a pre-revenue clinical-stage biotech. The key catalyst is positive interim Phase 1 data for JADE101 (IgA nephropathy) showing ~70% IgA reductions and potential for every-12-week dosing, plus unveiling of JADE301 for dermatomyositis. The $172.5M public offering extended cash runway into Q4 2028, but net loss widened to -$55.8M from -$32.1M YoY on higher R&D spend.
Key Financial Metrics
Key Facts
- Positive interim Phase 1 JADE101 data: ~70% mean IgA reduction after single 700mg dose, supporting every-12-week maintenance dosing
- Phase 2 JUNIPER trial in IgAN underway; registrational Phase 3 expected H1 2027
- Unveiled JADE301 (anti-IFN-β) for dermatomyositis; Phase 1 healthy volunteer trial now expected Q4 2026
- Completed $172.5M public offering; cash $461.2M as of June 30, 2026, runway into Q4 2028
- Net loss -$55.8M vs -$32.1M YoY; R&D expense $50.1M vs $22.5M YoY
- Shares outstanding ~83.9M as of June 30, 2026 (up from ~70.7M at March 31, 2026)
Financial Impact
Cash position $461.2M provides runway into Q4 2028; net loss -$55.8M for Q2 2026
Risk Factors
- Phase 2/3 clinical failure risk for JADE101
- Competitive landscape in IgAN (e.g., Travere's FILSPARI, Novartis's iptacopan)
- Dilution from $172.5M offering (~19% share increase)
- Pre-revenue with widening losses; no approved products
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-341229 |
| Document: d40629d8k.htm | 0001193125-26-341229 |
| Document: 0001193125-26-341229-index-headers.html | 0001193125-26-341229 |
| Document: 0001193125-26-341229-index.html | 0001193125-26-341229 |
| Document: 0001193125-26-341229.txt | 0001193125-26-341229 |
| 8-K Data (Synthetic) | 0001193125-26-341229 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 27d ago | 8-K | $14.05 $13.77 | ▼ −1.99% | ▼ −3.91% | $14.92 (+6.19%) |
Aug 10, 2026 11w ago | 8-K | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.92 (−31.34%) |
Aug 10, 2026 11w ago | Press Release | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.92 (−31.34%) |
Jun 5, 2026 20w ago | Press Release | $14.98 $16.10 | ▼ −7.48% | ▼ −5.37% | $14.92 (+0.40%) |
Jun 4, 2026 20w ago | 8-K | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.92 (+11.92%) |
Jun 4, 2026 20w ago | 424B5 | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.92 (+11.92%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.92 (+15.90%) |
Jun 3, 2026 20w ago | 424B5 | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.92 (+15.90%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.92 (+15.90%) |
Jun 1, 2026 21w ago | 8-K | $18.59 $16.94 | ▼ −8.88% | ▼ −6.13% | $14.92 (−19.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers